RegisterLogin

ASX-173

CAT: 0804-HY-175282-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-175282-01Size:5 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ASX-173 is an orally active inhibitor of asparagine synthetase (ASNS) (IC50 = 0.113 μM, Ki = 0.4 nM) . ASX-173 enhances the anticancer activity of L-asparaginase (ASNase) (HY-P1923) . ASX-173 disrupts nucleotide synthesis and induces leukemia cell cycle arrest, apoptosis and autophagy in leukemia cells in combination with ASNase. ASX-173 slows the growth of OCI-AML2 xenografts in combination with ASNase. ASX-173 is indicated for the study of acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers[1].
CAS Number
[2748800-08-8]
UNSPSC
12352005
Target
Akt; Apoptosis; Atg8/LC3; Autophagy; Caspase; CDK; PARP
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR
Field of Research
Cancer
Smiles
CC[C@@H](C(N1C[C@@H](C2=CC=C(C=C2)F)[C@H](O)[C@@H]1C(NC(C3=CC=CC=C3)C4=CC=CC=C4)=O)=O)N
Molecular Formula
C28H30FN3O3
Molecular Weight
475.55
References & Citations
[1]Victor Tatarskiy , et al. The ASNS inhibitor ASX-173 potentiates L-asparaginase anticancer activity.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Caspase 3

Related Products

CatalogName
HY-175864EGFR-IN-173
HY-15868-01HS-173
HY-163563-01JYQ-173
HY-118248HW 173
HY-161821Antitumor agent-173
HY-129909Anticancer agent 173
HY-P5829ACRAMP (140-173) (mouse) (TFA)
HY-173253E3 Ligase Ligand-linker Conjugate 173
HY-P990254-01Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173)
HY-12151-01NS 1738

Alternative Products

CatalogName
T211828-01ASX-173
MBS1354192Recombinant Drosophila melanogaster Polycomb protein Asx (Asx), partial
M13357-01MAP3K14-IN-173
451982-01HS-173
MBS5775234HW 173
T209952-01JYQ-173
ABC-TC455SBV-173

Popular Products